A new malaria medicine developed in partnership by sigma-tau and MMV
The European Medicines Agency (EMA) has approved Eurartesim, dihydroartemisininpiperaquine (DHA/PQP), developed in partnership by sigma-tau and MMV for the treatment of uncomplicated P. falciparum malaria.
Over the last 10 years DHA-PQP has been used widely and demonstrated effectiveness as a key treatment against malaria in the private sector. Until now, the public sector had no access to it as it had not been approved by a stringent regulatory authority and thus could not be procured using international donor funds. The approval of Eurartesim, by the EMA is now set to change that.
Sigma-tau and MMV will continue to work together to ensure the medicine will soon be made available to as many physicians and health workers caring for people suffering from malaria as possible, particularly in malaria-endemic countries. This medicine now has the potential to save many thousands of lives.